41.9% of US adults meet the obesity threshold, but comorbidity segments, not the headline count, decide who gets covered.

Obesity is a chronic, relapsing metabolic disease defined by a body-mass index of 30 or greater. CDC NHANES data put US adult obesity prevalence at 41.9%, roughly 100 million adults, with severe obesity (BMI 40 or above) affecting 9.2%, about 22 million people. The most recent NHANES cycle shows age-adjusted obesity at 40.3% and severe obesity at 9.7%, up from 30.5% in 1999-2000. The disease stratifies into Class I (30-34.9), Class II (35-39.9), and Class III or severe (40 and above), each carrying a different comorbidity load and a different treatment and coverage rationale.

The clinical case for treatment now rests on outcomes, not weight alone. Two GLP-1 agents dominate: semaglutide 2.4mg (Wegovy, Novo Nordisk) delivered 15.3% weight loss in the STEP 1 trial, while tirzepatide (Zepbound, Eli Lilly) delivered 20.9% at its 15mg dose in SURMOUNT-1, a clear head-to-head efficacy gap. The SELECT trial then showed semaglutide cut major adverse cardiovascular events by 20% in adults with obesity and established cardiovascular disease but without diabetes, converting obesity from a cosmetic indication into a cardiovascular one. That evidence reframes the addressable population around comorbidity-defined segments that payers and Medicare will actually fund.

BMI alone no longer decides who gets treated or who gets paid for.

Five questions this report answers:

Q1 - How does the US obesity population stratify by BMI class and comorbidity?

Q2 - How does GLP-1 head-to-head efficacy in obesity map to patient segmentation?

Q3 - How large is the comorbidity-linked population anchoring obesity coverage, CVD and type 2 diabetes?

Q4 - How many US adults have obesity, and how is severe obesity defined?

Q5 - Which obesity segment opened Medicare coverage, and why does comorbidity outweigh BMI alone?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#Obesity #GLP1 #Cardiometabolic #USHealthcare #DiseaseLandscape

Live report page:  https://axlrx.ai/obesity/disease-landscape/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-                    hello@axlrx.ai

Web-                    https://axlrx.ai/